Nabi Pharmaceuticals (NABI)

Company

"Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim™ (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in its core business areas: hepatitis and transplant, kidney disease (nephrology), Gram-positive bacterial infections and nicotine addiction." (company website)

NABI 3-month stock chart

Buy

21-Sep-06. NABI has been moving up from a recent low and pulled back about 40% from the latest high. For the past two weeks it has been following the 1-month moving average up.

  • Price momentum (PPO) — slowing has slowed
  • Trend (ADX) — selling pressure (-DI) has fallen away from buying pressure (+DI), although the trend isn't all that strong
  • Money flow (CMF) — strong flow of money into the stock
  • Relative strength (RSI) — strengthening over past two months
  • Volume — daily average is falling, which is worrisome

Sell

gain Bottom line
2%

28-Sep-06. I got into NABI as an early buy, despite some weaknesses in the chart, on the strength of a short-term uptrend, following the 1-month moving average and improvement from being over-sold (StochRSI). Yesterday, a major stockholder re-asserted pressure for NABI to explore options to "increase shareholder value" such as a sale. Looking at the weakening since I bought, I decided to sell today if there was any kind of bounce in reaction to the news.

NABI 1-year chart
NABI 1-year chart